Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

active_not_recruiting117%
completed583%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_2

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT06465186
completedphase_2

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

NCT05877547
completedphase_1

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

NCT06052566
completedphase_2

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
completedphase_1

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

NCT06701305
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06465186Phase 2

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Active Not Recruiting
NCT05877547Phase 2

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Completed
NCT06052566Phase 1

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Completed
NCT06482112Phase 2

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Completed
NCT06701305Phase 1

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

Completed
NCT06836037Phase 1

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

Completed

All 6 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
6